Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis
Source abstract
Abstract
Metastasis is the major cause for breast cancer related mortality. The combination of miRNA-based therapy and chemotherapy represents a promising approach against breast cancer lung metastasis. The goal of this study is to develop an improved therapy that co-delivers a novel bioengineered miRNA prodrug (tRNA-mir-34a) and doxorubicin (DOX) via a multifunctional nanomicellar carrier that is based on a conjugate of amphiphilic copolymer POEG-VBC backbone with creatine, a naturally occurring cationic molecule. Co-delivery of DOX leads to more effective processing of tRNA-mir-34a into mature miR-34a and down-regulation of target genes. DOX + tRNA-mir-34a/POEG-PCre exhibits potent synergistic anti-tumor and anti-metastasis activity in vitro and in vivo. Interestingly, the enhanced immune response contributes to the overall antitumor efficacy. POEG-PCre may represent a safe and effective delivery system for an optimal chemo-gene combination therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · RNA modifications and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world10.1200/JCO.2005.05.2308 ↗
2. Genes that mediate breast cancer metastasis to lung10.1038/nature03799 ↗
3. Breast cancer metastasis: markers and models10.1038/nrc1670 ↗
4. Triple-negative breast cancer10.1056/NEJMra1001389 ↗
5. Triple-negative breast cancer: disease entity or title of convenience?10.1038/nrclinonc.2010.154 ↗
6. Triple-negative breast cancer: clinical features and patterns of recurrence10.1158/1078-0432.CCR-06-3045 ↗
7. A review of systemic treatment in metastatic triple-negative breast cancer
8. MicroRNAs: genomics, biogenesis, mechanism, and function10.1016/S0092-8674(04)00045-5 ↗
9. Gene silencing by microRNAs: contributions of translational repression and mRNA decay10.1038/nrg2936 ↗
10. The promise of MicroRNA replacement therapy10.1158/0008-5472.CAN-10-2010 ↗
11. The miR-34 family in cancer and apoptosis10.1038/cdd.2009.56 ↗
12. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas10.1517/14728222.2016.1114102 ↗
13. First microRNA mimic enters clinic10.1038/nbt0713-577 ↗
14. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications10.1093/nar/gkv228 ↗
15. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization10.1124/jpet.115.225631 ↗
16. Viral and nonviral delivery systems for gene delivery10.4103/2277-9175.98152 ↗
17. Design and development of polymers for gene delivery10.1038/nrd1775 ↗
18. Nonviral vectors for gene delivery10.1021/cr800409e ↗
19. Advanced materials for Co-delivery of drugs and genes in cancer therapy10.1002/adhm.201200109 ↗
20. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles10.1016/j.jconrel.2008.05.010 ↗
21. Synthesis of diblock/statistical cationic glycopolymers with pendant galactose and lysine moieties: gene delivery application and intracellular behaviors10.1039/C6TB00969G ↗
22. Transferrin-polycation conjugates as carriers for DNA uptake into cells10.1073/pnas.87.9.3410 ↗
23. PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery10.1038/ncomms11822 ↗
24. Liposomal gene delivery: a complex package10.1038/nbt0797-620 ↗
25. Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions10.1152/ajplung.2000.278.3.L417 ↗
26. Novel glucosylceramide synthase inhibitor based prodrug copolymer micelles for delivery of anticancer agents10.1016/j.jconrel.2018.09.011 ↗
27. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT110.1007/s10238-012-0186-5 ↗
28. A microRNA mir-34a-regulated bimodal switch targets Notch in colon cancer stem cells10.1016/j.stem.2013.03.002 ↗
29. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease10.1038/nrclinonc.2016.66 ↗
30. Adjuvant treatments for triple-negative breast cancers10.1093/annonc/mds194 ↗
31. A review of efficacy and safety
32. Creatine supplementation with specific view to exercise/sports performance: an update10.1186/1550-2783-9-33 ↗
33. Creatine and creatinine metabolism10.1152/physrev.2000.80.3.1107 ↗
34. Development of microRNA therapeutics is coming of age10.15252/emmm.201100899 ↗
35. Development of therapeutic-grade small interfering RNAs by chemical engineering
36. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment10.1016/j.apsb.2015.03.001 ↗
37. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice10.1038/mt.2011.48 ↗
38. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure10.1016/j.jconrel.2009.10.027 ↗
39. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers10.1016/j.biotechadv.2014.05.006 ↗
40. Microscopic investigations into PEG−Cationic polymer-induced DNA condensation10.1021/la001456x ↗
41. Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles10.1016/j.jconrel.2015.09.046 ↗
42. M.M. Amiji, Polymeric Gene Delivery : Principles and Applications, CRC2005.10.1201/9780203500477 ↗
43. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections10.7150/thno.9404 ↗
44. Chemical basis of interactions between engineered nanoparticles and biological systems10.1021/cr400295a ↗
45. Extended weak bonding interactions in DNA: π-stacking (Base−Base), Base−Backbone, and Backbone−Backbone interactions10.1021/jp054986g ↗
46. The design of guanidinium-rich transporters and their internalization mechanisms10.1016/j.addr.2007.10.016 ↗
47. Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications10.1021/ar4000554 ↗
48. Viral mimicking ternary polyplexes: a reduction-controlled hierarchical unpacking vector for gene delivery10.1002/adma.201304592 ↗
49. Virion-like membrane-breaking nanoparticles with tumor-activated cell-and-tissue dual-penetration conquer impermeable cancer
50. Tailoring the supramolecular structure of guanidinylated pullulan toward enhanced genetic photodynamic therapy10.1021/acs.biomac.8b00273 ↗
51. BRG1 and SMARCAL1 transcriptionally co-regulate DROSHA, DGCR8 and DICER in response to doxorubicin-induced DNA damage10.1016/j.bbagrm.2017.07.003 ↗
52. Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy10.1084/jem.20100269 ↗
53. Bioengineered ncRNAs selectively change cellular miRNome profiles for cancer therapy10.1124/jpet.118.247775 ↗
54. A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications10.1093/nar/gkv228 ↗
55. Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs10.1080/1061186X.2017.1419355 ↗
56. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy10.1038/ncomms13443 ↗